Develops antibody therapies for autoimmune and inflammatory diseases such as celiac disease, with a pipeline inherited at spinoff.
Develops antibody therapies for autoimmune and inflammatory diseases such as celiac disease, with a pipeline inherited at spinoff.
Has no product revenue, so it runs on the cash it started with and on further share sales while its antibodies are tested; value comes from trial results, possibly followed by licensing the programs to larger drug makers. It is newly separate from its former parent.
Moat: none (IP / patents). Inherited a differentiated antibody pipeline at spinoff, but is newly independent with no approved products.
Headquarters: San Diego, California, US · Founded: 2019
Size First Tracks Biotherapeutics (TRAX) is a United States Health Care company (Biotechnology) with a market value of $1.87B, the 1812th largest of 3,085 United States companies the cockpit tracks. Shares closed at $44.50 on 18 Nov 2026.
Performance Over six months the shares gained 175.3%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Short interest Short interest is 12.0% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$2.42M | -$2.40M |
| EBITDA | n/a | -$177M | -$179M |
| Net income | n/a | -$166M | -$164M |
| Free cash flow | n/a | -$143M | -$126M |
| Capital expenditure | n/a | $87,000 | $358,000 |
| Total debt | $3.77M | $14.1M | $16.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics TRAX | $1.87B | +175% | n/a | n/a | n/a | n/a |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 3.2× | 3.7% |
| AnaptysBio ANAB | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TRAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.9% | -6.2% | 4th highest of 20 |
| 6-month return | +175.3% | -4.7% | 2nd highest of 19 |
| Distance from 52-week high | -18.8% | -34.3% | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |